Multinational specialty bio-pharmaceutical company.
Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021; Issues related to S. 4231 - Preparing for the Next Pandemic Act; Issues related to S. 1624 - HEALS Act; Issues related to H.R. 2466 - The State Opioid Response Grant Authorization Act; Issues related to H.R. 7574 - Strengthening Americas Strategic National Stockpile Act of 2020; Issues related to H.R. 133 Consolidated Appropriations Act, 2021. Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021; Issues related to H.R. 133 Consolidated Appropriations Act, 2021. Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021; Issues related to H.R. 925 - The Heroes Act; Issues related to S. 4231 - Preparing for the Next Pandemic Act; Issues related to S. 1624 - HEALS Act; Issues related to H.R. 2466 - The State Opioid Response Grant Authorization Act; Issues related to H.R. 7574 - Strengthening Americas Strategic National Stockpile Act of 2020; Issues related to H.R. 133 Consolidated Appropriations Act, 2021. Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021; Issues related to S. 4231 - Preparing for the Next Pandemic Act; Issues related to S. 1624 - HEALS Act; Issues related to H.R. 2466 - The State Opioid Response Grant Authorization Act; Issues related to H.R. 7574 - Strengthening Americas Strategic National Stockpile Act of 2020; Issues related to H.R. 133 Consolidated Appropriations Act, 2021.
DIS - Disaster Planning/Emergencies HCR - Health Issues BUD - Budget/Appropriations HOM - Homeland Security
134 - Centers For Disease Control & Prevention (CDC) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 37 - Justice, Dept of (DOJ) 18 - Office of Management & Budget (OMB) 19 - Office of Natl Drug Control Policy (NDCP) 1 - SENATE 141 - Substance Abuse & Mental Health Services Administration (SAMHSA) 134 - Centers For Disease Control & Prevention (CDC) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 37 - Justice, Dept of (DOJ) 18 - Office of Management & Budget (OMB) 19 - Office of Natl Drug Control Policy (NDCP) 1 - SENATE 141 - Substance Abuse & Mental Health Services Administration (SAMHSA) 134 - Centers For Disease Control & Prevention (CDC) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 37 - Justice, Dept of (DOJ) 18 - Office of Management & Budget (OMB) 19 - Office of Natl Drug Control Policy (NDCP) 1 - SENATE 141 - Substance Abuse & Mental Health Services Administration (SAMHSA) 134 - Centers For Disease Control & Prevention (CDC) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 37 - Justice, Dept of (DOJ) 18 - Office of Management & Budget (OMB) 19 - Office of Natl Drug Control Policy (NDCP) 1 - SENATE 141 - Substance Abuse & Mental Health Services Administration (SAMHSA)
FORBES-TATE
777 6th Street NW, 8th Floor, Washington, DC, 20001, US
EDWARD C. RENO DERRICK M WHITE JEFFREY SADOSKY JERRY DRISCOLL ZACHARY WILLIAMS WESLEY RYAN WELCH ELIZABETH GREER RICK MURPHY KRISTINA DUNKLIN FRANCESCA MCCRARY CYNTHIA BROWN (Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002)) CYNTHIA BROWN (Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002)) EDWARD C. RENO DERRICK M WHITE JEFFREY SADOSKY JERRY DRISCOLL ZACHARY WILLIAMS WESLEY RYAN WELCH ELIZABETH GREER RICK MURPHY KRISTINA DUNKLIN FRANCESCA MCCRARY EDWARD C. RENO DERRICK M WHITE JEFFREY SADOSKY JERRY DRISCOLL ZACHARY WILLIAMS WESLEY RYAN WELCH ELIZABETH GREER RICK MURPHY KRISTINA DUNKLIN FRANCESCA MCCRARY CYNTHIA BROWN (Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002)) EDWARD C. RENO DERRICK M WHITE JEFFREY SADOSKY JERRY DRISCOLL ZACHARY WILLIAMS WESLEY RYAN WELCH ELIZABETH GREER RICK MURPHY KRISTINA DUNKLIN FRANCESCA MCCRARY CYNTHIA BROWN (Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002))
Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002) Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002) Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002) Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002)